| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Hormones | 130 | 2024 | 330 | 13.130 |
Why?
|
| Thyroid Hormone Resistance Syndrome | 59 | 2024 | 117 | 10.710 |
Why?
|
| Thyrotropin | 116 | 2024 | 289 | 8.270 |
Why?
|
| Mutation | 126 | 2024 | 4159 | 8.050 |
Why?
|
| Thyroid Gland | 91 | 2024 | 280 | 7.120 |
Why?
|
| Triiodothyronine | 119 | 2024 | 345 | 7.110 |
Why?
|
| Congenital Hypothyroidism | 42 | 2023 | 79 | 6.930 |
Why?
|
| Receptors, Thyroid Hormone | 71 | 2018 | 160 | 6.550 |
Why?
|
| Thyroxine | 131 | 2024 | 354 | 6.000 |
Why?
|
| Thyroid Hormone Receptors beta | 33 | 2023 | 80 | 5.570 |
Why?
|
| Monocarboxylic Acid Transporters | 32 | 2024 | 83 | 5.400 |
Why?
|
| Symporters | 38 | 2024 | 108 | 4.840 |
Why?
|
| Thyroxine-Binding Proteins | 68 | 2015 | 86 | 4.780 |
Why?
|
| Hypothyroidism | 66 | 2024 | 242 | 4.590 |
Why?
|
| Receptors, Thyrotropin | 24 | 2017 | 47 | 4.210 |
Why?
|
| Mental Retardation, X-Linked | 7 | 2024 | 31 | 3.690 |
Why?
|
| Muscular Atrophy | 8 | 2024 | 46 | 3.670 |
Why?
|
| Pedigree | 93 | 2024 | 970 | 3.430 |
Why?
|
| Thyroid Diseases | 31 | 2024 | 105 | 3.370 |
Why?
|
| Muscle Hypotonia | 10 | 2024 | 48 | 3.150 |
Why?
|
| Iodide Peroxidase | 33 | 2023 | 206 | 3.050 |
Why?
|
| Membrane Transport Proteins | 18 | 2017 | 170 | 3.040 |
Why?
|
| Goiter | 25 | 2022 | 43 | 2.540 |
Why?
|
| Thyroid Function Tests | 59 | 2022 | 120 | 2.490 |
Why?
|
| Hyperthyroxinemia, Familial Dysalbuminemic | 5 | 2020 | 8 | 2.410 |
Why?
|
| Thyroglobulin | 31 | 2023 | 59 | 2.350 |
Why?
|
| Propylthiouracil | 9 | 2024 | 27 | 1.880 |
Why?
|
| Antithyroid Agents | 7 | 2024 | 23 | 1.830 |
Why?
|
| Humans | 372 | 2024 | 89567 | 1.790 |
Why?
|
| Male | 252 | 2024 | 42464 | 1.760 |
Why?
|
| Dual Oxidases | 9 | 2020 | 14 | 1.670 |
Why?
|
| Membrane Proteins | 15 | 2019 | 1227 | 1.650 |
Why?
|
| Drug Resistance | 32 | 2017 | 232 | 1.630 |
Why?
|
| Liver | 34 | 2021 | 1208 | 1.620 |
Why?
|
| Phenotype | 42 | 2021 | 2447 | 1.610 |
Why?
|
| Hyperthyroidism | 23 | 2020 | 75 | 1.610 |
Why?
|
| Female | 240 | 2024 | 46371 | 1.570 |
Why?
|
| Mutation, Missense | 15 | 2020 | 280 | 1.550 |
Why?
|
| Animals | 189 | 2024 | 27476 | 1.540 |
Why?
|
| Nuclear Proteins | 12 | 2016 | 726 | 1.510 |
Why?
|
| Thyroid Neoplasms | 23 | 2023 | 425 | 1.490 |
Why?
|
| Homozygote | 20 | 2018 | 201 | 1.470 |
Why?
|
| Point Mutation | 17 | 2012 | 245 | 1.450 |
Why?
|
| Child, Preschool | 45 | 2024 | 3754 | 1.410 |
Why?
|
| Pituitary Gland | 32 | 2017 | 119 | 1.410 |
Why?
|
| Diiodothyronines | 4 | 2015 | 12 | 1.380 |
Why?
|
| Propionates | 4 | 2015 | 33 | 1.380 |
Why?
|
| Mice, Knockout | 51 | 2023 | 2012 | 1.360 |
Why?
|
| Mice | 93 | 2024 | 11828 | 1.340 |
Why?
|
| Iodine | 15 | 2023 | 43 | 1.280 |
Why?
|
| Child | 72 | 2024 | 7214 | 1.270 |
Why?
|
| Triiodothyronine, Reverse | 10 | 2021 | 32 | 1.220 |
Why?
|
| RNA-Binding Proteins | 6 | 2011 | 277 | 1.210 |
Why?
|
| Enhancer Elements, Genetic | 3 | 2024 | 284 | 1.200 |
Why?
|
| Serum Albumin | 10 | 2018 | 127 | 1.190 |
Why?
|
| Thyroid Dysgenesis | 5 | 2022 | 9 | 1.180 |
Why?
|
| Chromosomes, Human, Pair 15 | 2 | 2024 | 66 | 1.170 |
Why?
|
| Base Sequence | 56 | 2013 | 2329 | 1.150 |
Why?
|
| Genotype | 34 | 2023 | 1853 | 1.130 |
Why?
|
| Heterozygote | 23 | 2021 | 373 | 1.080 |
Why?
|
| Hyperthyroxinemia | 7 | 2011 | 17 | 1.070 |
Why?
|
| Terminology as Topic | 8 | 2017 | 221 | 1.050 |
Why?
|
| Infant | 32 | 2024 | 3174 | 0.970 |
Why?
|
| Genes, erbA | 4 | 2023 | 10 | 0.970 |
Why?
|
| Transcription Factors | 18 | 2020 | 1662 | 0.960 |
Why?
|
| Inheritance Patterns | 3 | 2021 | 48 | 0.950 |
Why?
|
| Carrier Proteins | 6 | 2019 | 678 | 0.950 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2024 | 118 | 0.930 |
Why?
|
| Thyroxine-Binding Globulin | 2 | 2015 | 6 | 0.930 |
Why?
|
| Placenta | 3 | 2023 | 181 | 0.910 |
Why?
|
| Syndrome | 25 | 2017 | 449 | 0.900 |
Why?
|
| Microsatellite Repeats | 1 | 2024 | 148 | 0.900 |
Why?
|
| Molecular Sequence Data | 49 | 2013 | 3024 | 0.880 |
Why?
|
| Nerve Tissue Proteins | 3 | 2016 | 511 | 0.860 |
Why?
|
| Adolescent | 59 | 2024 | 9299 | 0.860 |
Why?
|
| Adult | 115 | 2021 | 26684 | 0.840 |
Why?
|
| Neonatal Screening | 2 | 2021 | 64 | 0.820 |
Why?
|
| NADPH Oxidases | 5 | 2012 | 82 | 0.810 |
Why?
|
| RNA, Messenger | 38 | 2023 | 2021 | 0.800 |
Why?
|
| Circadian Rhythm | 17 | 2019 | 304 | 0.780 |
Why?
|
| Infant, Newborn | 29 | 2021 | 2487 | 0.780 |
Why?
|
| Dried Blood Spot Testing | 1 | 2021 | 10 | 0.770 |
Why?
|
| Thyrotropin, beta Subunit | 4 | 2020 | 10 | 0.760 |
Why?
|
| Gene Expression Regulation | 18 | 2017 | 1982 | 0.760 |
Why?
|
| Albumins | 3 | 2020 | 129 | 0.740 |
Why?
|
| Fetal Therapies | 1 | 2020 | 6 | 0.730 |
Why?
|
| Pregnancy | 35 | 2023 | 3035 | 0.710 |
Why?
|
| Thyrotoxicosis | 7 | 2008 | 18 | 0.700 |
Why?
|
| Trans-Activators | 5 | 2017 | 443 | 0.690 |
Why?
|
| Iodides | 9 | 2022 | 18 | 0.670 |
Why?
|
| Amino Acid Sequence | 35 | 2007 | 2063 | 0.660 |
Why?
|
| Brain | 12 | 2020 | 2294 | 0.660 |
Why?
|
| Thyrotropin-Releasing Hormone | 19 | 2017 | 40 | 0.660 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 104 | 0.660 |
Why?
|
| MicroRNAs | 1 | 2024 | 555 | 0.650 |
Why?
|
| Arabs | 4 | 2012 | 16 | 0.650 |
Why?
|
| Genetic Association Studies | 3 | 2020 | 294 | 0.650 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2011 | 217 | 0.630 |
Why?
|
| Serum Albumin, Human | 1 | 2018 | 5 | 0.620 |
Why?
|
| Circadian Clocks | 1 | 2019 | 63 | 0.620 |
Why?
|
| Thyroid Hormone Receptors alpha | 6 | 2020 | 22 | 0.620 |
Why?
|
| Mice, Inbred C57BL | 22 | 2022 | 3237 | 0.620 |
Why?
|
| PAX8 Transcription Factor | 10 | 2022 | 23 | 0.620 |
Why?
|
| Fibroblasts | 19 | 2019 | 758 | 0.590 |
Why?
|
| Selenium | 4 | 2011 | 46 | 0.590 |
Why?
|
| DNA-Binding Proteins | 7 | 2021 | 1243 | 0.580 |
Why?
|
| Endocrinology | 1 | 2018 | 49 | 0.570 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2021 | 2354 | 0.570 |
Why?
|
| Haplotypes | 13 | 2015 | 636 | 0.560 |
Why?
|
| Anion Transport Proteins | 1 | 2016 | 10 | 0.550 |
Why?
|
| Flavoproteins | 2 | 2007 | 25 | 0.550 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 714 | 0.550 |
Why?
|
| Prenatal Diagnosis | 4 | 2017 | 110 | 0.540 |
Why?
|
| Paired Box Transcription Factors | 8 | 2022 | 52 | 0.530 |
Why?
|
| Alleles | 20 | 2015 | 1136 | 0.530 |
Why?
|
| Interleukin-4 | 1 | 2016 | 129 | 0.530 |
Why?
|
| Iron-Binding Proteins | 3 | 2021 | 15 | 0.530 |
Why?
|
| Selenoproteins | 3 | 2011 | 21 | 0.530 |
Why?
|
| Consanguinity | 7 | 2015 | 73 | 0.530 |
Why?
|
| DNA | 30 | 2017 | 1309 | 0.510 |
Why?
|
| Exons | 16 | 2007 | 453 | 0.500 |
Why?
|
| Up-Regulation | 3 | 2020 | 725 | 0.500 |
Why?
|
| Autoantigens | 3 | 2021 | 129 | 0.490 |
Why?
|
| Pituitary Neoplasms | 13 | 2016 | 69 | 0.470 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 5 | 1997 | 188 | 0.470 |
Why?
|
| Genetic Linkage | 9 | 2009 | 624 | 0.470 |
Why?
|
| DNA Mutational Analysis | 12 | 2020 | 529 | 0.460 |
Why?
|
| Disease Models, Animal | 17 | 2022 | 2384 | 0.460 |
Why?
|
| Energy Metabolism | 9 | 2023 | 280 | 0.460 |
Why?
|
| Iodine Radioisotopes | 26 | 2013 | 134 | 0.460 |
Why?
|
| Amino Acid Substitution | 12 | 2020 | 338 | 0.450 |
Why?
|
| Biological Transport | 10 | 2014 | 401 | 0.450 |
Why?
|
| Prolactin | 24 | 1999 | 89 | 0.450 |
Why?
|
| Radioimmunoassay | 21 | 2011 | 155 | 0.450 |
Why?
|
| Mice, Transgenic | 16 | 2023 | 1576 | 0.430 |
Why?
|
| Polymerase Chain Reaction | 15 | 2011 | 919 | 0.430 |
Why?
|
| Middle Aged | 52 | 2021 | 25996 | 0.420 |
Why?
|
| Cells, Cultured | 24 | 2016 | 2884 | 0.420 |
Why?
|
| Protein Biosynthesis | 16 | 2010 | 388 | 0.400 |
Why?
|
| Genetic Variation | 11 | 2004 | 1380 | 0.400 |
Why?
|
| Signal Transduction | 10 | 2020 | 3395 | 0.390 |
Why?
|
| COS Cells | 10 | 2009 | 167 | 0.380 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 14 | 2016 | 885 | 0.370 |
Why?
|
| Goiter, Nodular | 3 | 2020 | 7 | 0.360 |
Why?
|
| Thyroiditis, Autoimmune | 5 | 2005 | 17 | 0.360 |
Why?
|
| Rats | 48 | 2022 | 4041 | 0.360 |
Why?
|
| Endoplasmic Reticulum | 3 | 2023 | 255 | 0.360 |
Why?
|
| Thyroid Nuclear Factor 1 | 6 | 2019 | 12 | 0.350 |
Why?
|
| Microfilament Proteins | 2 | 2021 | 212 | 0.350 |
Why?
|
| Carcinoma | 4 | 2019 | 438 | 0.340 |
Why?
|
| Promoter Regions, Genetic | 12 | 2018 | 961 | 0.340 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2021 | 312 | 0.340 |
Why?
|
| Cell Nucleus | 12 | 2010 | 601 | 0.330 |
Why?
|
| Fatty Liver | 2 | 2021 | 96 | 0.330 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2020 | 43 | 0.330 |
Why?
|
| Repressor Proteins | 5 | 2017 | 423 | 0.330 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2023 | 86 | 0.330 |
Why?
|
| Diseases in Twins | 2 | 2012 | 65 | 0.320 |
Why?
|
| Body Height | 1 | 2009 | 100 | 0.320 |
Why?
|
| Autoantibodies | 9 | 2010 | 268 | 0.320 |
Why?
|
| Gene Deletion | 5 | 2011 | 341 | 0.310 |
Why?
|
| Thyroid Epithelial Cells | 4 | 2021 | 5 | 0.310 |
Why?
|
| Hypothalamus | 6 | 2023 | 79 | 0.310 |
Why?
|
| Lysosomes | 3 | 2019 | 113 | 0.310 |
Why?
|
| Biomarkers | 6 | 2023 | 1768 | 0.310 |
Why?
|
| Growth Hormone | 20 | 2002 | 96 | 0.310 |
Why?
|
| Myopathies, Structural, Congenital | 1 | 2008 | 10 | 0.300 |
Why?
|
| Developmental Disabilities | 2 | 2020 | 202 | 0.300 |
Why?
|
| Adenoma | 5 | 2016 | 250 | 0.300 |
Why?
|
| Alternative Splicing | 3 | 2004 | 212 | 0.290 |
Why?
|
| Genes, Dominant | 4 | 2005 | 117 | 0.290 |
Why?
|
| Young Adult | 7 | 2021 | 6362 | 0.290 |
Why?
|
| Hydrogen Peroxide | 5 | 2022 | 158 | 0.290 |
Why?
|
| Genes | 7 | 1996 | 306 | 0.280 |
Why?
|
| Transfection | 16 | 2011 | 909 | 0.280 |
Why?
|
| Thyroidectomy | 8 | 2012 | 171 | 0.280 |
Why?
|
| Isoenzymes | 3 | 2015 | 274 | 0.280 |
Why?
|
| Cell Line | 18 | 2018 | 2494 | 0.270 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2019 | 156 | 0.270 |
Why?
|
| DNA, Complementary | 11 | 2004 | 391 | 0.270 |
Why?
|
| Mosaicism | 1 | 2006 | 70 | 0.270 |
Why?
|
| Recombinant Proteins | 8 | 2005 | 1008 | 0.270 |
Why?
|
| Skin | 7 | 2009 | 589 | 0.260 |
Why?
|
| Mice, Inbred Strains | 4 | 2020 | 308 | 0.260 |
Why?
|
| Glycolysis | 2 | 2011 | 135 | 0.260 |
Why?
|
| Cystinosis | 2 | 2016 | 2 | 0.260 |
Why?
|
| Lingual Goiter | 1 | 2005 | 1 | 0.260 |
Why?
|
| Histone Acetyltransferases | 6 | 2009 | 42 | 0.250 |
Why?
|
| Pregnancy Complications | 6 | 2017 | 345 | 0.250 |
Why?
|
| Proline | 3 | 2003 | 55 | 0.250 |
Why?
|
| Cerebral Cortex | 7 | 2019 | 589 | 0.250 |
Why?
|
| Family | 6 | 2020 | 325 | 0.250 |
Why?
|
| Reference Values | 7 | 2020 | 661 | 0.250 |
Why?
|
| Cloning, Molecular | 10 | 2002 | 645 | 0.250 |
Why?
|
| Catecholamines | 3 | 2004 | 92 | 0.250 |
Why?
|
| Kinetics | 17 | 2020 | 1534 | 0.250 |
Why?
|
| Cholesterol | 7 | 2006 | 360 | 0.250 |
Why?
|
| Germ-Line Mutation | 1 | 2008 | 346 | 0.250 |
Why?
|
| Response Elements | 1 | 2005 | 69 | 0.250 |
Why?
|
| Gene Expression | 10 | 2016 | 1309 | 0.250 |
Why?
|
| Adipose Tissue | 2 | 2021 | 260 | 0.250 |
Why?
|
| Family Health | 3 | 2018 | 162 | 0.250 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2004 | 6 | 0.250 |
Why?
|
| Hot Temperature | 15 | 2002 | 207 | 0.250 |
Why?
|
| Body Temperature | 5 | 2023 | 125 | 0.240 |
Why?
|
| Sequence Analysis, DNA | 6 | 2018 | 868 | 0.240 |
Why?
|
| Alkaline Phosphatase | 4 | 2006 | 132 | 0.240 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2011 | 268 | 0.240 |
Why?
|
| Hormones | 5 | 2010 | 139 | 0.240 |
Why?
|
| Israel | 4 | 2012 | 57 | 0.230 |
Why?
|
| Insulin Resistance | 2 | 2021 | 353 | 0.230 |
Why?
|
| Metabolism, Inborn Errors | 5 | 2004 | 30 | 0.230 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2011 | 146 | 0.230 |
Why?
|
| Aged | 30 | 2022 | 19144 | 0.230 |
Why?
|
| Hypothalamo-Hypophyseal System | 3 | 2017 | 81 | 0.230 |
Why?
|
| Arginine | 3 | 2015 | 138 | 0.230 |
Why?
|
| Aging | 3 | 2002 | 721 | 0.230 |
Why?
|
| Diagnosis, Differential | 11 | 2015 | 1605 | 0.230 |
Why?
|
| 5' Untranslated Regions | 1 | 2004 | 52 | 0.230 |
Why?
|
| Cell Proliferation | 4 | 2022 | 1668 | 0.230 |
Why?
|
| Codon | 8 | 2009 | 123 | 0.230 |
Why?
|
| Early Diagnosis | 2 | 2021 | 125 | 0.230 |
Why?
|
| Acid Sensing Ion Channels | 1 | 2023 | 1 | 0.230 |
Why?
|
| Twins, Monozygotic | 1 | 2003 | 58 | 0.220 |
Why?
|
| Intellectual Disability | 4 | 2005 | 189 | 0.220 |
Why?
|
| Enzyme Activation | 10 | 2017 | 696 | 0.220 |
Why?
|
| Leydig Cells | 1 | 2003 | 11 | 0.220 |
Why?
|
| Gene Expression Profiling | 5 | 2016 | 1445 | 0.220 |
Why?
|
| Chromosomes, Human, X | 1 | 2003 | 55 | 0.220 |
Why?
|
| Endocrine System Diseases | 2 | 1993 | 23 | 0.220 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 2 | 2020 | 16 | 0.220 |
Why?
|
| Blood-Brain Barrier | 2 | 2017 | 75 | 0.220 |
Why?
|
| Transcription, Genetic | 11 | 2010 | 1158 | 0.220 |
Why?
|
| Diiodotyrosine | 1 | 2023 | 3 | 0.220 |
Why?
|
| RNA | 9 | 2005 | 581 | 0.220 |
Why?
|
| Organ Specificity | 4 | 2014 | 274 | 0.210 |
Why?
|
| Autoimmune Diseases | 5 | 2013 | 250 | 0.210 |
Why?
|
| Antioxidants | 2 | 2018 | 226 | 0.210 |
Why?
|
| Frameshift Mutation | 4 | 2006 | 51 | 0.210 |
Why?
|
| Chorea | 2 | 2017 | 12 | 0.210 |
Why?
|
| Primates | 1 | 2024 | 155 | 0.210 |
Why?
|
| Myocardium | 4 | 2017 | 572 | 0.210 |
Why?
|
| Maternal-Fetal Exchange | 7 | 2017 | 77 | 0.210 |
Why?
|
| Mast Cells | 1 | 2022 | 94 | 0.210 |
Why?
|
| Prealbumin | 2 | 1996 | 34 | 0.210 |
Why?
|
| Drug Therapy, Combination | 1 | 2024 | 782 | 0.200 |
Why?
|
| Fetus | 2 | 2023 | 232 | 0.200 |
Why?
|
| Th17 Cells | 1 | 2023 | 85 | 0.200 |
Why?
|
| Organoids | 1 | 2022 | 63 | 0.200 |
Why?
|
| Leukocyte Elastase | 1 | 2002 | 8 | 0.200 |
Why?
|
| Radionuclide Imaging | 6 | 2005 | 222 | 0.200 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2019 | 158 | 0.200 |
Why?
|
| Genes, Recessive | 2 | 2012 | 87 | 0.200 |
Why?
|
| Nuclear Receptor Coactivator 1 | 6 | 2009 | 24 | 0.200 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2001 | 44 | 0.200 |
Why?
|
| Cardiomyopathies | 1 | 2004 | 265 | 0.200 |
Why?
|
| Sleep Deprivation | 8 | 1995 | 138 | 0.190 |
Why?
|
| Ovarian Follicle | 1 | 2021 | 72 | 0.190 |
Why?
|
| Autophagy | 2 | 2023 | 159 | 0.190 |
Why?
|
| Protein Conformation | 6 | 2015 | 895 | 0.190 |
Why?
|
| Oxidation-Reduction | 5 | 2019 | 388 | 0.190 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2001 | 114 | 0.190 |
Why?
|
| Hydrocortisone | 10 | 1994 | 301 | 0.190 |
Why?
|
| Chromosome Deletion | 2 | 1992 | 226 | 0.190 |
Why?
|
| Polymorphism, Genetic | 7 | 2005 | 825 | 0.180 |
Why?
|
| Growth Disorders | 4 | 2022 | 63 | 0.180 |
Why?
|
| Growth | 2 | 2000 | 43 | 0.180 |
Why?
|
| Amniotic Fluid | 1 | 2020 | 30 | 0.180 |
Why?
|
| Codon, Nonsense | 3 | 2018 | 44 | 0.180 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2016 | 693 | 0.180 |
Why?
|
| Treatment Outcome | 4 | 2024 | 8209 | 0.180 |
Why?
|
| Evaluation Studies as Topic | 3 | 2019 | 270 | 0.180 |
Why?
|
| Argentina | 1 | 2020 | 13 | 0.180 |
Why?
|
| Bone and Bones | 3 | 2017 | 271 | 0.180 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2020 | 60 | 0.180 |
Why?
|
| Isoelectric Focusing | 10 | 2006 | 39 | 0.180 |
Why?
|
| Chromogranins | 1 | 2020 | 11 | 0.180 |
Why?
|
| Neurons | 4 | 2017 | 1588 | 0.180 |
Why?
|
| Administration, Intranasal | 1 | 2020 | 139 | 0.170 |
Why?
|
| Class III Phosphatidylinositol 3-Kinases | 1 | 2019 | 2 | 0.170 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2020 | 19 | 0.170 |
Why?
|
| Alu Elements | 1 | 2020 | 16 | 0.170 |
Why?
|
| Turkey | 2 | 2013 | 21 | 0.170 |
Why?
|
| X Chromosome | 7 | 1989 | 153 | 0.170 |
Why?
|
| Cell Dedifferentiation | 1 | 2019 | 8 | 0.170 |
Why?
|
| Binding Sites | 13 | 2002 | 1120 | 0.170 |
Why?
|
| Pituitary Gland, Anterior | 9 | 2014 | 22 | 0.170 |
Why?
|
| Dietary Supplements | 2 | 2011 | 124 | 0.170 |
Why?
|
| Glycogen Storage Disease Type I | 1 | 2019 | 5 | 0.170 |
Why?
|
| Jet Lag Syndrome | 1 | 2019 | 13 | 0.170 |
Why?
|
| Serine | 2 | 2005 | 105 | 0.170 |
Why?
|
| Graves Disease | 8 | 2004 | 36 | 0.170 |
Why?
|
| Mitochondria, Liver | 1 | 2019 | 28 | 0.170 |
Why?
|
| Christianity | 2 | 1999 | 37 | 0.170 |
Why?
|
| Bone Development | 4 | 2017 | 37 | 0.170 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 76 | 0.170 |
Why?
|
| Adrenocorticotropic Hormone | 10 | 2012 | 131 | 0.170 |
Why?
|
| Mutagenesis, Insertional | 1 | 2020 | 114 | 0.170 |
Why?
|
| Organophosphonates | 1 | 2019 | 51 | 0.170 |
Why?
|
| Carcinoma, Papillary | 3 | 2011 | 156 | 0.170 |
Why?
|
| Receptors, Steroid | 2 | 1999 | 42 | 0.160 |
Why?
|
| Heart | 2 | 2001 | 574 | 0.160 |
Why?
|
| Organogenesis | 2 | 2016 | 50 | 0.160 |
Why?
|
| Cell Differentiation | 6 | 2023 | 1529 | 0.160 |
Why?
|
| Antiporters | 1 | 2018 | 18 | 0.160 |
Why?
|
| Disease Progression | 1 | 2023 | 1463 | 0.160 |
Why?
|
| Transcriptional Activation | 7 | 2010 | 294 | 0.160 |
Why?
|
| Estrogens | 4 | 2010 | 200 | 0.160 |
Why?
|
| Protein Denaturation | 12 | 2000 | 106 | 0.160 |
Why?
|
| Tretinoin | 3 | 1999 | 128 | 0.160 |
Why?
|
| Polymorphism, Restriction Fragment Length | 4 | 2007 | 147 | 0.160 |
Why?
|
| Protein Multimerization | 1 | 2020 | 178 | 0.160 |
Why?
|
| Pituitary Diseases | 3 | 2004 | 5 | 0.160 |
Why?
|
| Alpha-Globulins | 4 | 1983 | 11 | 0.160 |
Why?
|
| Netherlands | 1 | 2018 | 24 | 0.160 |
Why?
|
| Protein Binding | 17 | 2005 | 1491 | 0.150 |
Why?
|
| Down-Regulation | 4 | 2016 | 520 | 0.150 |
Why?
|
| Cell Membrane | 3 | 2013 | 675 | 0.150 |
Why?
|
| Pregnancy Outcome | 3 | 2017 | 258 | 0.150 |
Why?
|
| Founder Effect | 2 | 2012 | 104 | 0.150 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 1850 | 0.150 |
Why?
|
| Embryonic Stem Cells | 2 | 2022 | 81 | 0.150 |
Why?
|
| Proteins | 5 | 2004 | 786 | 0.150 |
Why?
|
| Fetal Diseases | 3 | 2017 | 82 | 0.150 |
Why?
|
| Intestinal Mucosa | 1 | 2023 | 805 | 0.150 |
Why?
|
| Athetosis | 1 | 2017 | 4 | 0.150 |
Why?
|
| International Cooperation | 1 | 2018 | 125 | 0.150 |
Why?
|
| Adipose Tissue, Brown | 5 | 2013 | 86 | 0.150 |
Why?
|
| Pituitary-Adrenal System | 1 | 2017 | 64 | 0.150 |
Why?
|
| Adenoviridae | 3 | 1997 | 349 | 0.150 |
Why?
|
| Symptom Assessment | 1 | 2018 | 66 | 0.150 |
Why?
|
| Receptors, Thyrotropin-Releasing Hormone | 1 | 2017 | 2 | 0.140 |
Why?
|
| Carnitine | 1 | 2017 | 14 | 0.140 |
Why?
|
| Congresses as Topic | 1 | 2018 | 114 | 0.140 |
Why?
|
| Psychomotor Disorders | 1 | 2017 | 20 | 0.140 |
Why?
|
| Cyclic AMP | 7 | 2010 | 275 | 0.140 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2017 | 54 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2020 | 2411 | 0.140 |
Why?
|
| Obesity | 1 | 2004 | 971 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2020 | 3465 | 0.140 |
Why?
|
| Cerebellum | 2 | 2016 | 249 | 0.140 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 3658 | 0.140 |
Why?
|
| Oncogenes | 1 | 2017 | 97 | 0.140 |
Why?
|
| Glutathione Transferase | 2 | 2015 | 112 | 0.140 |
Why?
|
| Absorption, Physiological | 1 | 2016 | 1 | 0.140 |
Why?
|
| Cattle | 11 | 2017 | 378 | 0.140 |
Why?
|
| Cellular Senescence | 1 | 2017 | 100 | 0.140 |
Why?
|
| Leukocytes | 5 | 2002 | 208 | 0.140 |
Why?
|
| Smad5 Protein | 1 | 2016 | 1 | 0.140 |
Why?
|
| Smad1 Protein | 1 | 2016 | 3 | 0.140 |
Why?
|
| Blood Protein Disorders | 4 | 1983 | 8 | 0.130 |
Why?
|
| Immunoglobulins | 1 | 2017 | 143 | 0.130 |
Why?
|
| Congenital Hyperinsulinism | 1 | 2016 | 14 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 1727 | 0.130 |
Why?
|
| Leptin | 3 | 2004 | 102 | 0.130 |
Why?
|
| Time Factors | 23 | 2017 | 5333 | 0.130 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 1995 | 4 | 0.130 |
Why?
|
| Models, Biological | 3 | 2007 | 1762 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 4 | 2015 | 1394 | 0.130 |
Why?
|
| Basement Membrane | 1 | 2016 | 55 | 0.130 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1862 | 0.130 |
Why?
|
| Glycerol-3-Phosphate Dehydrogenase (NAD+) | 1 | 2015 | 5 | 0.130 |
Why?
|
| Drinking | 1 | 2015 | 33 | 0.130 |
Why?
|
| Muscle Proteins | 3 | 2005 | 133 | 0.130 |
Why?
|
| Pakistan | 1 | 2015 | 15 | 0.130 |
Why?
|
| Injections, Intraperitoneal | 1 | 2015 | 101 | 0.130 |
Why?
|
| Gene Knockout Techniques | 2 | 2013 | 82 | 0.130 |
Why?
|
| Estradiol | 8 | 1996 | 250 | 0.130 |
Why?
|
| Transcriptome | 2 | 2022 | 654 | 0.130 |
Why?
|
| MAP Kinase Signaling System | 3 | 2011 | 197 | 0.130 |
Why?
|
| Cushing Syndrome | 2 | 1985 | 24 | 0.130 |
Why?
|
| Mutagenesis, Site-Directed | 4 | 2009 | 283 | 0.130 |
Why?
|
| Gene Transfer Techniques | 1 | 1996 | 153 | 0.120 |
Why?
|
| Glycosaminoglycans | 4 | 2000 | 47 | 0.120 |
Why?
|
| Sudan | 3 | 2020 | 13 | 0.120 |
Why?
|
| Cricetinae | 6 | 2006 | 558 | 0.120 |
Why?
|
| Mice, 129 Strain | 2 | 2012 | 56 | 0.120 |
Why?
|
| Tooth Abnormalities | 1 | 2015 | 6 | 0.120 |
Why?
|
| Glycine | 1 | 2015 | 95 | 0.120 |
Why?
|
| Hyperkinesis | 1 | 2015 | 15 | 0.120 |
Why?
|
| Educational Status | 1 | 1995 | 195 | 0.120 |
Why?
|
| Brain Damage, Chronic | 1 | 2014 | 26 | 0.120 |
Why?
|
| Muscle, Skeletal | 2 | 2015 | 469 | 0.120 |
Why?
|
| Xenopus | 5 | 2004 | 126 | 0.120 |
Why?
|
| Unfolded Protein Response | 1 | 2015 | 43 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 517 | 0.120 |
Why?
|
| Drug Administration Schedule | 4 | 2004 | 865 | 0.120 |
Why?
|
| Gene Amplification | 6 | 1994 | 135 | 0.120 |
Why?
|
| Tooth | 1 | 2015 | 51 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 5 | 1998 | 1048 | 0.120 |
Why?
|
| Fasting | 4 | 2006 | 162 | 0.120 |
Why?
|
| Chromosome Mapping | 6 | 2007 | 1074 | 0.120 |
Why?
|
| Shrews | 2 | 2006 | 5 | 0.120 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2014 | 37 | 0.120 |
Why?
|
| Eating | 1 | 2015 | 167 | 0.120 |
Why?
|
| Myelin Sheath | 1 | 2014 | 85 | 0.120 |
Why?
|
| Retrospective Studies | 7 | 2021 | 9112 | 0.120 |
Why?
|
| Crosses, Genetic | 2 | 2012 | 171 | 0.110 |
Why?
|
| Luteinizing Hormone | 6 | 2003 | 167 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2011 | 137 | 0.110 |
Why?
|
| Receptors, Cell Surface | 7 | 1995 | 288 | 0.110 |
Why?
|
| Analysis of Variance | 2 | 2017 | 899 | 0.110 |
Why?
|
| Indoles | 2 | 2014 | 300 | 0.110 |
Why?
|
| Prevalence | 5 | 2020 | 1247 | 0.110 |
Why?
|
| Leucine | 3 | 1999 | 60 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2018 | 402 | 0.110 |
Why?
|
| Thailand | 3 | 2016 | 57 | 0.110 |
Why?
|
| Canada | 1 | 2014 | 208 | 0.110 |
Why?
|
| Testosterone | 6 | 2005 | 272 | 0.110 |
Why?
|
| Monoiodotyrosine | 2 | 2023 | 4 | 0.110 |
Why?
|
| Methimazole | 7 | 2010 | 13 | 0.110 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2015 | 200 | 0.110 |
Why?
|
| Pyrroles | 1 | 2014 | 172 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 194 | 0.110 |
Why?
|
| Bangladesh | 1 | 2014 | 331 | 0.110 |
Why?
|
| Neurotransmitter Agents | 1 | 2013 | 108 | 0.110 |
Why?
|
| Liver Neoplasms | 4 | 2004 | 753 | 0.110 |
Why?
|
| Endothelial Cells | 1 | 2016 | 462 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2014 | 383 | 0.110 |
Why?
|
| Compassionate Use Trials | 1 | 2012 | 6 | 0.110 |
Why?
|
| Protein Isoforms | 8 | 2006 | 276 | 0.100 |
Why?
|
| Cell Line, Tumor | 4 | 2020 | 2582 | 0.100 |
Why?
|
| Isotope Labeling | 7 | 1978 | 52 | 0.100 |
Why?
|
| Receptors, Somatostatin | 1 | 2012 | 34 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2004 | 396 | 0.100 |
Why?
|
| Feedback, Physiological | 3 | 2007 | 66 | 0.100 |
Why?
|
| Gene Expression Regulation, Developmental | 4 | 2016 | 663 | 0.100 |
Why?
|
| Models, Molecular | 2 | 2015 | 1313 | 0.100 |
Why?
|
| Cell Movement | 1 | 2016 | 785 | 0.100 |
Why?
|
| DNA Primers | 4 | 2004 | 543 | 0.100 |
Why?
|
| Glycoproteins | 2 | 2010 | 234 | 0.100 |
Why?
|
| Animals, Newborn | 6 | 2014 | 524 | 0.100 |
Why?
|
| Pseudohypoparathyroidism | 1 | 1992 | 5 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 164 | 0.100 |
Why?
|
| Mothers | 2 | 2017 | 143 | 0.100 |
Why?
|
| Gene Frequency | 5 | 2020 | 687 | 0.100 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2012 | 11 | 0.100 |
Why?
|
| Cardiotonic Agents | 1 | 2012 | 89 | 0.100 |
Why?
|
| Nucleic Acid Hybridization | 9 | 2011 | 243 | 0.100 |
Why?
|
| Follicle Stimulating Hormone | 5 | 2003 | 147 | 0.100 |
Why?
|
| Receptors, Retinoic Acid | 3 | 2002 | 47 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 2327 | 0.100 |
Why?
|
| Neoplasm Proteins | 2 | 2011 | 538 | 0.100 |
Why?
|
| Dexamethasone | 6 | 1996 | 342 | 0.100 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2011 | 31 | 0.100 |
Why?
|
| Binding, Competitive | 4 | 2002 | 146 | 0.100 |
Why?
|
| Hydrolases | 1 | 2011 | 30 | 0.100 |
Why?
|
| Microsurgery | 1 | 2012 | 90 | 0.090 |
Why?
|
| Oligosaccharides | 2 | 1988 | 24 | 0.090 |
Why?
|
| Protein Folding | 2 | 2018 | 290 | 0.090 |
Why?
|
| Rats, Inbred Strains | 9 | 1991 | 312 | 0.090 |
Why?
|
| Osmolar Concentration | 3 | 2007 | 182 | 0.090 |
Why?
|
| Acute Lung Injury | 1 | 2011 | 64 | 0.090 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2011 | 72 | 0.090 |
Why?
|
| Regeneration | 1 | 2012 | 151 | 0.090 |
Why?
|
| Drug Stability | 4 | 2002 | 51 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2010 | 13 | 0.090 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 6 | 1997 | 269 | 0.090 |
Why?
|
| Child Development | 1 | 2012 | 166 | 0.090 |
Why?
|
| Feedback | 4 | 2001 | 134 | 0.090 |
Why?
|
| Receptor Cross-Talk | 1 | 2010 | 33 | 0.090 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 1 | 2010 | 3 | 0.090 |
Why?
|
| Hypoproteinemia | 1 | 1990 | 1 | 0.090 |
Why?
|
| Amino Acids | 2 | 2002 | 246 | 0.090 |
Why?
|
| Oocytes | 5 | 2004 | 219 | 0.090 |
Why?
|
| Age Factors | 4 | 2020 | 1877 | 0.090 |
Why?
|
| Psychomotor Performance | 2 | 2012 | 497 | 0.090 |
Why?
|
| Research Design | 1 | 2013 | 586 | 0.090 |
Why?
|
| Restriction Mapping | 4 | 1995 | 154 | 0.090 |
Why?
|
| Oligodeoxyribonucleotides | 4 | 1995 | 125 | 0.090 |
Why?
|
| Organ Size | 4 | 2013 | 370 | 0.090 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2010 | 55 | 0.090 |
Why?
|
| Dystonic Disorders | 1 | 2009 | 7 | 0.090 |
Why?
|
| Dependovirus | 2 | 2022 | 34 | 0.090 |
Why?
|
| Body Weight | 6 | 2017 | 453 | 0.090 |
Why?
|
| Ghana | 1 | 2009 | 4 | 0.080 |
Why?
|
| Heart Rate | 5 | 2001 | 498 | 0.080 |
Why?
|
| Movement Disorders | 1 | 2009 | 44 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 3 | 2009 | 740 | 0.080 |
Why?
|
| Pituitary Hormones, Anterior | 2 | 1985 | 4 | 0.080 |
Why?
|
| Serum | 1 | 2009 | 25 | 0.080 |
Why?
|
| Molecular Structure | 1 | 2010 | 292 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2011 | 318 | 0.080 |
Why?
|
| In Vitro Techniques | 8 | 2019 | 996 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 2 | 2022 | 171 | 0.080 |
Why?
|
| Inositol Phosphates | 2 | 2007 | 16 | 0.080 |
Why?
|
| Immunohistochemistry | 6 | 2011 | 1798 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2011 | 412 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2016 | 888 | 0.080 |
Why?
|
| Neoplasms, Radiation-Induced | 3 | 1980 | 109 | 0.080 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1989 | 101 | 0.080 |
Why?
|
| Blood Proteins | 9 | 1991 | 149 | 0.080 |
Why?
|
| Autoimmunity | 1 | 2010 | 169 | 0.080 |
Why?
|
| Myxedema | 2 | 1980 | 3 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 123 | 0.080 |
Why?
|
| Glycosylation | 4 | 2014 | 128 | 0.080 |
Why?
|
| Creatine Kinase | 3 | 2005 | 52 | 0.080 |
Why?
|
| Nuclear Family | 1 | 2008 | 93 | 0.080 |
Why?
|
| Age of Onset | 1 | 2009 | 314 | 0.080 |
Why?
|
| Sex Chromosomes | 3 | 1980 | 57 | 0.080 |
Why?
|
| Carbohydrate Metabolism | 2 | 1986 | 29 | 0.080 |
Why?
|
| Melatonin | 4 | 1994 | 50 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2010 | 327 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 165 | 0.070 |
Why?
|
| Sialic Acids | 1 | 1987 | 18 | 0.070 |
Why?
|
| Electroencephalography | 4 | 2003 | 754 | 0.070 |
Why?
|
| Species Specificity | 4 | 2011 | 685 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2017 | 2304 | 0.070 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-2 | 2 | 2005 | 2 | 0.070 |
Why?
|
| Polysaccharides | 2 | 2007 | 90 | 0.070 |
Why?
|
| Radiotherapy | 2 | 1983 | 332 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 585 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2020 | 646 | 0.070 |
Why?
|
| Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase | 1 | 2007 | 7 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2001 | 563 | 0.070 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2004 | 81 | 0.070 |
Why?
|
| Blotting, Western | 5 | 2011 | 793 | 0.070 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2007 | 50 | 0.070 |
Why?
|
| Introns | 5 | 2007 | 301 | 0.070 |
Why?
|
| Sex Hormone-Binding Globulin | 3 | 2005 | 20 | 0.070 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 559 | 0.070 |
Why?
|
| DNA, Recombinant | 2 | 1998 | 67 | 0.070 |
Why?
|
| Gene Dosage | 2 | 2011 | 210 | 0.070 |
Why?
|
| Adrenal Glands | 3 | 2004 | 77 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 2364 | 0.070 |
Why?
|
| Islam | 1 | 2007 | 34 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 449 | 0.070 |
Why?
|
| Birth Weight | 3 | 2017 | 148 | 0.070 |
Why?
|
| Corticotropin-Releasing Hormone | 4 | 2012 | 44 | 0.070 |
Why?
|
| Operon | 1 | 2006 | 50 | 0.070 |
Why?
|
| Oxidative Stress | 2 | 2020 | 457 | 0.070 |
Why?
|
| Sequence Analysis, Protein | 1 | 2006 | 28 | 0.070 |
Why?
|
| Multigene Family | 2 | 1999 | 202 | 0.070 |
Why?
|
| GTP-Binding Proteins | 2 | 1997 | 145 | 0.070 |
Why?
|
| LDL-Receptor Related Protein-Associated Protein | 1 | 2005 | 1 | 0.070 |
Why?
|
| Brain Chemistry | 1 | 2006 | 122 | 0.070 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2005 | 11 | 0.070 |
Why?
|
| Amino Acid Transport Systems, Neutral | 2 | 2016 | 5 | 0.060 |
Why?
|
| Phosphofructokinase-1, Type C | 1 | 2005 | 2 | 0.060 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2005 | 17 | 0.060 |
Why?
|
| History, 20th Century | 2 | 2000 | 312 | 0.060 |
Why?
|
| Chromones | 1 | 2005 | 31 | 0.060 |
Why?
|
| Luciferases | 4 | 2005 | 128 | 0.060 |
Why?
|
| Blotting, Southern | 3 | 2005 | 127 | 0.060 |
Why?
|
| Nervous System Diseases | 1 | 1986 | 164 | 0.060 |
Why?
|
| RNA, Transfer, Amino Acyl | 1 | 1985 | 10 | 0.060 |
Why?
|
| Protein Transport | 1 | 2007 | 421 | 0.060 |
Why?
|
| Blood Protein Electrophoresis | 6 | 1986 | 15 | 0.060 |
Why?
|
| Sequence Deletion | 2 | 1998 | 205 | 0.060 |
Why?
|
| Morpholines | 1 | 2005 | 70 | 0.060 |
Why?
|
| Siblings | 1 | 2005 | 110 | 0.060 |
Why?
|
| Sleep Stages | 5 | 1991 | 47 | 0.060 |
Why?
|
| Hypopituitarism | 2 | 1978 | 19 | 0.060 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2005 | 35 | 0.060 |
Why?
|
| Cytosol | 1 | 2005 | 193 | 0.060 |
Why?
|
| Metanephrine | 1 | 2004 | 6 | 0.060 |
Why?
|
| Lung | 1 | 2011 | 1273 | 0.060 |
Why?
|
| Amyloidosis | 1 | 1986 | 130 | 0.060 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2004 | 20 | 0.060 |
Why?
|
| Uremia | 2 | 1984 | 14 | 0.060 |
Why?
|
| Plasmids | 4 | 2006 | 291 | 0.060 |
Why?
|
| Kruppel-Like Transcription Factors | 2 | 2019 | 101 | 0.060 |
Why?
|
| Databases, Genetic | 1 | 2006 | 269 | 0.060 |
Why?
|
| Skin Physiological Phenomena | 1 | 2004 | 27 | 0.060 |
Why?
|
| Adrenalectomy | 1 | 2004 | 45 | 0.060 |
Why?
|
| Dimerization | 1 | 2004 | 143 | 0.060 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2004 | 46 | 0.060 |
Why?
|
| Labor, Obstetric | 1 | 2004 | 46 | 0.060 |
Why?
|
| Pheochromocytoma | 1 | 2004 | 49 | 0.060 |
Why?
|
| Evolution, Molecular | 3 | 2006 | 851 | 0.060 |
Why?
|
| Australia | 3 | 2018 | 101 | 0.060 |
Why?
|
| Genetic Testing | 2 | 2007 | 539 | 0.060 |
Why?
|
| Protein Sorting Signals | 1 | 2004 | 43 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2019 | 571 | 0.060 |
Why?
|
| Nystagmus, Congenital | 1 | 2003 | 2 | 0.060 |
Why?
|
| CHO Cells | 4 | 2001 | 188 | 0.060 |
Why?
|
| Dosage Compensation, Genetic | 1 | 2003 | 17 | 0.060 |
Why?
|
| Iodine Isotopes | 8 | 1973 | 18 | 0.060 |
Why?
|
| Quadriplegia | 1 | 2003 | 23 | 0.060 |
Why?
|
| Oligonucleotide Probes | 2 | 1995 | 39 | 0.060 |
Why?
|
| Abortion, Spontaneous | 1 | 2004 | 66 | 0.060 |
Why?
|
| Genetic Structures | 1 | 2003 | 4 | 0.060 |
Why?
|
| Culture Media | 5 | 2009 | 147 | 0.060 |
Why?
|
| Fusion Regulatory Protein 1, Light Chains | 2 | 2013 | 6 | 0.060 |
Why?
|
| Amino Acid Transport System y+ | 2 | 2013 | 7 | 0.060 |
Why?
|
| Europe | 1 | 2024 | 322 | 0.060 |
Why?
|
| Organic Anion Transporters | 2 | 2013 | 26 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2010 | 1928 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2004 | 195 | 0.050 |
Why?
|
| Sirolimus | 1 | 2004 | 162 | 0.050 |
Why?
|
| Tissue Distribution | 3 | 2014 | 293 | 0.050 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2005 | 206 | 0.050 |
Why?
|
| Proteostasis | 1 | 2023 | 12 | 0.050 |
Why?
|
| Ligands | 5 | 2004 | 446 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2004 | 212 | 0.050 |
Why?
|
| Sleep | 5 | 1995 | 454 | 0.050 |
Why?
|
| Threonine | 1 | 2003 | 35 | 0.050 |
Why?
|
| Nucleic Acid Conformation | 1 | 2004 | 345 | 0.050 |
Why?
|
| Acetylation | 2 | 2016 | 132 | 0.050 |
Why?
|
| Pregnancy, Animal | 1 | 2003 | 58 | 0.050 |
Why?
|
| Biopsy | 3 | 2004 | 1183 | 0.050 |
Why?
|
| Cathepsin G | 1 | 2022 | 1 | 0.050 |
Why?
|
| Agranulocytosis | 1 | 1982 | 20 | 0.050 |
Why?
|
| Transferases | 1 | 1982 | 23 | 0.050 |
Why?
|
| Glycosyltransferases | 1 | 1982 | 19 | 0.050 |
Why?
|
| Xenopus Proteins | 1 | 1982 | 35 | 0.050 |
Why?
|
| Genes, Reporter | 4 | 2006 | 274 | 0.050 |
Why?
|
| DNA Damage | 2 | 2017 | 371 | 0.050 |
Why?
|
| Serum Globulins | 4 | 1977 | 12 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2004 | 337 | 0.050 |
Why?
|
| Serogroup | 1 | 2022 | 9 | 0.050 |
Why?
|
| Drug Eruptions | 1 | 1982 | 33 | 0.050 |
Why?
|
| Genetic Vectors | 3 | 2011 | 446 | 0.050 |
Why?
|
| Methylation | 2 | 2016 | 269 | 0.050 |
Why?
|
| In Situ Hybridization | 3 | 2007 | 313 | 0.050 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2002 | 16 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 642 | 0.050 |
Why?
|
| Ferritins | 2 | 2005 | 29 | 0.050 |
Why?
|
| Calcium | 1 | 2007 | 1178 | 0.050 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1982 | 65 | 0.050 |
Why?
|
| Eosinophilia | 1 | 1982 | 84 | 0.050 |
Why?
|
| Chromosome Segregation | 1 | 2002 | 32 | 0.050 |
Why?
|
| Triglycerides | 2 | 2019 | 233 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2002 | 258 | 0.050 |
Why?
|
| Adaptation, Physiological | 3 | 1999 | 314 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2001 | 22 | 0.050 |
Why?
|
| Central Nervous System Diseases | 1 | 2002 | 52 | 0.050 |
Why?
|
| Codon, Terminator | 2 | 1999 | 22 | 0.050 |
Why?
|
| RNA Splice Sites | 1 | 2002 | 58 | 0.050 |
Why?
|
| Albuminuria | 1 | 2001 | 48 | 0.050 |
Why?
|
| Immunoassay | 1 | 2022 | 91 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2022 | 168 | 0.050 |
Why?
|
| Genome | 2 | 1997 | 391 | 0.050 |
Why?
|
| Darkness | 2 | 1981 | 49 | 0.050 |
Why?
|
| Blood Glucose | 3 | 1995 | 837 | 0.050 |
Why?
|
| Turner Syndrome | 2 | 1973 | 27 | 0.050 |
Why?
|
| Cellular Reprogramming Techniques | 1 | 2020 | 6 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 3 | 1977 | 40 | 0.050 |
Why?
|
| Histones | 2 | 2016 | 333 | 0.050 |
Why?
|
| Early Medical Intervention | 1 | 2020 | 20 | 0.050 |
Why?
|
| Megalencephaly | 1 | 2020 | 21 | 0.050 |
Why?
|
| Pancreas | 2 | 1980 | 249 | 0.050 |
Why?
|
| Heredity | 1 | 2020 | 19 | 0.050 |
Why?
|
| Switzerland | 1 | 2000 | 17 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 665 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2017 | 341 | 0.050 |
Why?
|
| Acclimatization | 3 | 1990 | 76 | 0.040 |
Why?
|
| Macromolecular Substances | 3 | 1997 | 177 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 581 | 0.040 |
Why?
|
| Histidine | 2 | 2004 | 56 | 0.040 |
Why?
|
| Constipation | 1 | 2020 | 64 | 0.040 |
Why?
|
| Infusions, Intraventricular | 1 | 2019 | 5 | 0.040 |
Why?
|
| Methods | 7 | 1974 | 151 | 0.040 |
Why?
|
| Deafness | 5 | 2001 | 48 | 0.040 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2019 | 8 | 0.040 |
Why?
|
| Substrate Specificity | 1 | 2020 | 352 | 0.040 |
Why?
|
| Organelle Biogenesis | 1 | 2019 | 6 | 0.040 |
Why?
|
| Texas | 1 | 2000 | 116 | 0.040 |
Why?
|
| Immunoglobulin G | 3 | 2014 | 469 | 0.040 |
Why?
|
| Prospective Studies | 3 | 1997 | 4309 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2019 | 77 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2000 | 476 | 0.040 |
Why?
|
| DNA Transposable Elements | 2 | 1998 | 175 | 0.040 |
Why?
|
| Embryo, Mammalian | 2 | 2014 | 223 | 0.040 |
Why?
|
| Protein Domains | 1 | 2020 | 135 | 0.040 |
Why?
|
| Reference Standards | 1 | 1999 | 144 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 2666 | 0.040 |
Why?
|
| Lymphocytes | 2 | 1998 | 468 | 0.040 |
Why?
|
| Glycogen | 1 | 2019 | 59 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 3 | 2011 | 1090 | 0.040 |
Why?
|
| Proteolysis | 1 | 2019 | 111 | 0.040 |
Why?
|
| Diagnostic Errors | 2 | 2015 | 160 | 0.040 |
Why?
|
| Adenoma, Chromophobe | 1 | 1978 | 3 | 0.040 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1978 | 16 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2019 | 134 | 0.040 |
Why?
|
| Radiation Effects | 2 | 1975 | 28 | 0.040 |
Why?
|
| Neck | 2 | 1980 | 104 | 0.040 |
Why?
|
| Immunosorbent Techniques | 1 | 1998 | 13 | 0.040 |
Why?
|
| Islets of Langerhans | 2 | 1980 | 549 | 0.040 |
Why?
|
| Retina | 1 | 1980 | 220 | 0.040 |
Why?
|
| DNA, Antisense | 1 | 1998 | 15 | 0.040 |
Why?
|
| Exome | 1 | 2018 | 131 | 0.040 |
Why?
|
| Endocrine Glands | 1 | 1997 | 13 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2010 | 590 | 0.040 |
Why?
|
| Apoptosis | 2 | 2017 | 1717 | 0.040 |
Why?
|
| Gene Knock-In Techniques | 1 | 2017 | 29 | 0.040 |
Why?
|
| Chromatin | 3 | 2010 | 401 | 0.040 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 1998 | 45 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 29 | 0.040 |
Why?
|
| Placental Circulation | 1 | 2017 | 13 | 0.040 |
Why?
|
| Brazil | 1 | 1997 | 75 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2017 | 72 | 0.040 |
Why?
|
| Ribosomal Proteins | 1 | 2017 | 45 | 0.040 |
Why?
|
| Fluorescence | 1 | 1977 | 103 | 0.040 |
Why?
|
| Fetal Development | 1 | 2017 | 31 | 0.040 |
Why?
|
| Lipogenesis | 1 | 2017 | 23 | 0.040 |
Why?
|
| Carbohydrate Conformation | 2 | 1988 | 18 | 0.040 |
Why?
|
| Methionine | 3 | 1987 | 67 | 0.040 |
Why?
|
| Rabbits | 5 | 1997 | 639 | 0.040 |
Why?
|
| Polyribonucleotides | 1 | 1977 | 3 | 0.040 |
Why?
|
| Chondrocytes | 1 | 2017 | 64 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2018 | 285 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 794 | 0.040 |
Why?
|
| Dihydroxyphenylalanine | 2 | 1974 | 13 | 0.040 |
Why?
|
| Structure-Activity Relationship | 3 | 1999 | 413 | 0.040 |
Why?
|
| Adipogenesis | 1 | 2017 | 39 | 0.040 |
Why?
|
| Potassium Iodide | 1 | 1977 | 1 | 0.040 |
Why?
|
| Deoxyribonuclease EcoRI | 1 | 1996 | 7 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 2 | 1980 | 414 | 0.040 |
Why?
|
| Light | 3 | 1994 | 292 | 0.040 |
Why?
|
| Iran | 1 | 1996 | 15 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2017 | 152 | 0.040 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1996 | 31 | 0.040 |
Why?
|
| Random Allocation | 1 | 2017 | 327 | 0.040 |
Why?
|
| Receptors, LH | 1 | 1996 | 7 | 0.030 |
Why?
|
| Transplantation, Homologous | 3 | 2016 | 995 | 0.030 |
Why?
|
| Behavior | 1 | 1997 | 85 | 0.030 |
Why?
|
| Nafarelin | 1 | 1996 | 43 | 0.030 |
Why?
|
| Metabolomics | 1 | 2017 | 76 | 0.030 |
Why?
|
| Puberty, Precocious | 1 | 1996 | 36 | 0.030 |
Why?
|
| Peroneal Nerve | 1 | 1976 | 9 | 0.030 |
Why?
|
| Fibronectins | 2 | 1987 | 101 | 0.030 |
Why?
|
| Hungary | 1 | 2016 | 3 | 0.030 |
Why?
|
| Leg Dermatoses | 1 | 1976 | 7 | 0.030 |
Why?
|
| Paralysis | 1 | 1976 | 22 | 0.030 |
Why?
|
| Foot Diseases | 1 | 1976 | 12 | 0.030 |
Why?
|
| Valine | 1 | 1996 | 62 | 0.030 |
Why?
|
| RNA Splicing | 1 | 1998 | 156 | 0.030 |
Why?
|
| Nerve Compression Syndromes | 1 | 1976 | 19 | 0.030 |
Why?
|
| Hemagglutination Tests | 1 | 1976 | 11 | 0.030 |
Why?
|
| Jews | 1 | 2016 | 42 | 0.030 |
Why?
|
| Basal Metabolism | 3 | 1990 | 19 | 0.030 |
Why?
|
| Collagen Type IV | 1 | 2016 | 26 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 1997 | 387 | 0.030 |
Why?
|
| Molecular Biology | 2 | 1994 | 89 | 0.030 |
Why?
|
| Cell Transformation, Viral | 1 | 1996 | 38 | 0.030 |
Why?
|
| Cystine | 1 | 2016 | 15 | 0.030 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 2 | 2006 | 23 | 0.030 |
Why?
|
| Retinoid X Receptors | 3 | 2002 | 39 | 0.030 |
Why?
|
| Blood Vessels | 1 | 2016 | 94 | 0.030 |
Why?
|
| Homeostasis | 1 | 2018 | 417 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2006 | 73 | 0.030 |
Why?
|
| Laminin | 1 | 2016 | 89 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2016 | 103 | 0.030 |
Why?
|
| Chromatography, Ion Exchange | 2 | 1974 | 34 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 1987 | 503 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2001 | 1281 | 0.030 |
Why?
|
| Personality Assessment | 1 | 1995 | 97 | 0.030 |
Why?
|
| Autoradiography | 4 | 1986 | 69 | 0.030 |
Why?
|
| Intelligence | 1 | 1995 | 71 | 0.030 |
Why?
|
| Reticulocytes | 4 | 1995 | 25 | 0.030 |
Why?
|
| Child Behavior Disorders | 1 | 1995 | 76 | 0.030 |
Why?
|
| Thyronines | 3 | 1990 | 3 | 0.030 |
Why?
|
| Motor Skills | 1 | 2016 | 79 | 0.030 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2016 | 127 | 0.030 |
Why?
|
| Luminescent Proteins | 1 | 2016 | 144 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 490 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1997 | 492 | 0.030 |
Why?
|
| Immunization | 3 | 2003 | 163 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 1996 | 120 | 0.030 |
Why?
|
| Travel | 3 | 1985 | 71 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 743 | 0.030 |
Why?
|
| Wakefulness | 1 | 1995 | 135 | 0.030 |
Why?
|
| Lysine | 1 | 2016 | 150 | 0.030 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2015 | 7 | 0.030 |
Why?
|
| Adenylyl Cyclases | 1 | 1995 | 100 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2016 | 278 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 2015 | 0.030 |
Why?
|
| Defective Viruses | 1 | 1994 | 12 | 0.030 |
Why?
|
| Molecular Probes | 1 | 1995 | 35 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinase 2 | 1 | 2014 | 1 | 0.030 |
Why?
|
| Binding Sites, Antibody | 2 | 2004 | 49 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2014 | 10 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 2016 | 228 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2017 | 1130 | 0.030 |
Why?
|
| Cytosine Nucleotides | 1 | 1974 | 8 | 0.030 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2014 | 39 | 0.030 |
Why?
|
| Polynucleotides | 1 | 1974 | 17 | 0.030 |
Why?
|
| Physical Exertion | 1 | 1994 | 38 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 1995 | 131 | 0.030 |
Why?
|
| Behavior, Animal | 2 | 2013 | 378 | 0.030 |
Why?
|
| Diagnosis | 1 | 1994 | 18 | 0.030 |
Why?
|
| Benz(a)Anthracenes | 1 | 1974 | 4 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 405 | 0.030 |
Why?
|
| Psychological Tests | 1 | 1994 | 91 | 0.030 |
Why?
|
| Neurogenesis | 1 | 2014 | 77 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 1974 | 84 | 0.030 |
Why?
|
| Oligonucleotides | 1 | 1994 | 92 | 0.030 |
Why?
|
| Recombination, Genetic | 3 | 2003 | 446 | 0.030 |
Why?
|
| Molecular Weight | 3 | 1986 | 331 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2016 | 371 | 0.030 |
Why?
|
| Hepatoblastoma | 1 | 1993 | 12 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2016 | 305 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1 | 1 | 1993 | 30 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 1993 | 34 | 0.030 |
Why?
|
| Cerebrum | 1 | 2013 | 16 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2017 | 952 | 0.030 |
Why?
|
| Ovarian Diseases | 1 | 1973 | 32 | 0.030 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1974 | 111 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 2 | 2001 | 303 | 0.030 |
Why?
|
| Consensus Sequence | 1 | 1993 | 66 | 0.030 |
Why?
|
| Amino Acid Transport System y+L | 1 | 2013 | 3 | 0.030 |
Why?
|
| Organic Anion Transporters, Sodium-Independent | 1 | 2013 | 5 | 0.030 |
Why?
|
| Stem Cells | 1 | 2016 | 375 | 0.030 |
Why?
|
| Base Composition | 1 | 1993 | 36 | 0.030 |
Why?
|
| Niacin | 1 | 1993 | 37 | 0.030 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2013 | 13 | 0.030 |
Why?
|
| Radiotherapy Dosage | 3 | 1983 | 469 | 0.030 |
Why?
|
| Synapses | 1 | 2016 | 280 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 1994 | 101 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1993 | 137 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2011 | 1064 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 1993 | 80 | 0.030 |
Why?
|
| Chromatography, Affinity | 2 | 1988 | 81 | 0.030 |
Why?
|
| Half-Life | 3 | 1987 | 97 | 0.030 |
Why?
|
| Chiari-Frommel Syndrome | 1 | 1972 | 1 | 0.030 |
Why?
|
| DNA Restriction Enzymes | 2 | 1990 | 97 | 0.030 |
Why?
|
| Body Composition | 1 | 2013 | 71 | 0.030 |
Why?
|
| Oxygen | 1 | 2018 | 743 | 0.030 |
Why?
|
| Addison Disease | 1 | 1972 | 4 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 1997 | 1708 | 0.030 |
Why?
|
| Chromatography, Gel | 4 | 1982 | 103 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 305 | 0.030 |
Why?
|
| Escherichia coli | 2 | 1992 | 606 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1993 | 67 | 0.030 |
Why?
|
| Puerperal Disorders | 1 | 1972 | 32 | 0.030 |
Why?
|
| Immunoglobulins, Thyroid-Stimulating | 2 | 2004 | 5 | 0.030 |
Why?
|
| Kidney | 3 | 2002 | 1147 | 0.030 |
Why?
|
| Models, Animal | 1 | 2013 | 276 | 0.030 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1993 | 154 | 0.030 |
Why?
|
| Macrophages | 1 | 2016 | 578 | 0.030 |
Why?
|
| Sleep, REM | 3 | 1995 | 51 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1995 | 1237 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2012 | 6766 | 0.030 |
Why?
|
| Sequence Alignment | 2 | 2004 | 354 | 0.020 |
Why?
|
| Genes, Synthetic | 1 | 2011 | 7 | 0.020 |
Why?
|
| Diphenylamine | 1 | 2011 | 4 | 0.020 |
Why?
|
| Iopanoic Acid | 1 | 1991 | 4 | 0.020 |
Why?
|
| Adenine | 2 | 2004 | 88 | 0.020 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2011 | 15 | 0.020 |
Why?
|
| Aneuploidy | 1 | 2011 | 57 | 0.020 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2011 | 39 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2011 | 149 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2011 | 78 | 0.020 |
Why?
|
| gamma-Globulins | 1 | 1971 | 16 | 0.020 |
Why?
|
| Concanavalin A | 2 | 1988 | 52 | 0.020 |
Why?
|
| alpha 1-Antitrypsin | 2 | 1995 | 16 | 0.020 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1991 | 49 | 0.020 |
Why?
|
| Chemokines | 1 | 2011 | 74 | 0.020 |
Why?
|
| Homeobox Protein Nkx-2.5 | 1 | 2011 | 13 | 0.020 |
Why?
|
| DNA Probes | 1 | 1991 | 77 | 0.020 |
Why?
|
| Quebec | 1 | 1991 | 11 | 0.020 |
Why?
|
| Guanine | 2 | 2004 | 207 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1991 | 173 | 0.020 |
Why?
|
| Intestinal Absorption | 1 | 1991 | 125 | 0.020 |
Why?
|
| Mitosis | 1 | 2011 | 152 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2011 | 98 | 0.020 |
Why?
|
| Aerospace Medicine | 2 | 1981 | 17 | 0.020 |
Why?
|
| Complement System Proteins | 1 | 1971 | 82 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2011 | 371 | 0.020 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 1991 | 106 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 1996 | 740 | 0.020 |
Why?
|
| Insulin | 3 | 1995 | 1148 | 0.020 |
Why?
|
| Zebrafish | 1 | 2013 | 320 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2011 | 67 | 0.020 |
Why?
|
| Benzamides | 1 | 2011 | 234 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2011 | 294 | 0.020 |
Why?
|
| RNA, Ribosomal | 3 | 1977 | 68 | 0.020 |
Why?
|
| Guanethidine | 1 | 1990 | 3 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2010 | 36 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 604 | 0.020 |
Why?
|
| Gigantism | 1 | 1970 | 3 | 0.020 |
Why?
|
| Celiac Disease | 1 | 1973 | 214 | 0.020 |
Why?
|
| Acromegaly | 1 | 1970 | 5 | 0.020 |
Why?
|
| Asparagine | 1 | 1990 | 30 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2010 | 96 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 1990 | 64 | 0.020 |
Why?
|
| Periodicity | 2 | 1981 | 119 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 231 | 0.020 |
Why?
|
| Hypophysectomy | 3 | 1984 | 27 | 0.020 |
Why?
|
| Sympathetic Nervous System | 1 | 1990 | 96 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 137 | 0.020 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2009 | 31 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 3783 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 1974 | 571 | 0.020 |
Why?
|
| Exercise | 1 | 1993 | 326 | 0.020 |
Why?
|
| Phlebotomy | 1 | 2009 | 22 | 0.020 |
Why?
|
| Microsomes | 4 | 1977 | 35 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2009 | 88 | 0.020 |
Why?
|
| Neurogranin | 1 | 2009 | 3 | 0.020 |
Why?
|
| Peptides | 1 | 2012 | 649 | 0.020 |
Why?
|
| Neoplasms, Experimental | 6 | 1977 | 269 | 0.020 |
Why?
|
| Immunochemistry | 2 | 1987 | 16 | 0.020 |
Why?
|
| Acetates | 2 | 1982 | 67 | 0.020 |
Why?
|
| Thyroid Crisis | 1 | 1988 | 3 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2009 | 266 | 0.020 |
Why?
|
| Hepatitis | 1 | 1988 | 34 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 682 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1076 | 0.020 |
Why?
|
| Apoenzymes | 2 | 1986 | 7 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2000 | 689 | 0.020 |
Why?
|
| Spain | 1 | 2007 | 32 | 0.020 |
Why?
|
| Calcification, Physiologic | 1 | 2007 | 33 | 0.020 |
Why?
|
| Pituitary Function Tests | 1 | 1967 | 3 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2007 | 23 | 0.020 |
Why?
|
| Rats, Inbred Dahl | 1 | 2007 | 8 | 0.020 |
Why?
|
| Litter Size | 1 | 2007 | 13 | 0.020 |
Why?
|
| Rats, Inbred BN | 1 | 2007 | 38 | 0.020 |
Why?
|
| Osteoclasts | 1 | 2007 | 35 | 0.020 |
Why?
|
| Cytokines | 1 | 2011 | 806 | 0.020 |
Why?
|
| Precipitin Tests | 3 | 2003 | 111 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2012 | 2296 | 0.020 |
Why?
|
| Dialysis | 2 | 1985 | 24 | 0.020 |
Why?
|
| Osteoblasts | 1 | 2007 | 97 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 2763 | 0.020 |
Why?
|
| Chondrodysplasia Punctata | 1 | 1967 | 6 | 0.020 |
Why?
|
| Chromosomes | 1 | 2007 | 98 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2007 | 178 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2007 | 183 | 0.020 |
Why?
|
| Neoplasm Transplantation | 4 | 1977 | 397 | 0.020 |
Why?
|
| Prednisone | 2 | 1980 | 253 | 0.020 |
Why?
|
| Temperature | 3 | 1994 | 407 | 0.020 |
Why?
|
| Glucose Oxidase | 1 | 1986 | 7 | 0.020 |
Why?
|
| Glucosamine | 1 | 1986 | 10 | 0.020 |
Why?
|
| Mannose | 1 | 1986 | 9 | 0.020 |
Why?
|
| Fluorometry | 1 | 1986 | 30 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1986 | 38 | 0.020 |
Why?
|
| Haplorhini | 3 | 1971 | 81 | 0.020 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2006 | 122 | 0.020 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 1 | 2006 | 24 | 0.020 |
Why?
|
| Incidence | 1 | 2010 | 1598 | 0.020 |
Why?
|
| Stimulation, Chemical | 2 | 1977 | 63 | 0.020 |
Why?
|
| Diet | 1 | 2009 | 443 | 0.020 |
Why?
|
| Osteogenesis | 1 | 2007 | 258 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 2005 | 55 | 0.020 |
Why?
|
| Body Temperature Regulation | 3 | 1991 | 56 | 0.020 |
Why?
|
| Sulfur Radioisotopes | 1 | 1985 | 21 | 0.020 |
Why?
|
| Epinephrine | 3 | 1991 | 89 | 0.020 |
Why?
|
| Arousal | 3 | 1993 | 170 | 0.020 |
Why?
|
| Gene Targeting | 1 | 2005 | 74 | 0.020 |
Why?
|
| Thymus Gland | 3 | 1975 | 197 | 0.020 |
Why?
|
| Norepinephrine | 3 | 1991 | 172 | 0.020 |
Why?
|
| Phosphoserine | 1 | 2004 | 9 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2009 | 688 | 0.020 |
Why?
|
| Azores | 1 | 2004 | 3 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2005 | 333 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2004 | 16 | 0.020 |
Why?
|
| Cycloheximide | 1 | 2004 | 56 | 0.020 |
Why?
|
| Transgenes | 1 | 2005 | 185 | 0.010 |
Why?
|
| Thermodynamics | 1 | 2005 | 313 | 0.010 |
Why?
|
| Hybridomas | 1 | 2004 | 75 | 0.010 |
Why?
|
| Antibody Affinity | 2 | 1989 | 38 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2004 | 78 | 0.010 |
Why?
|
| Chromatography, Paper | 2 | 1975 | 11 | 0.010 |
Why?
|
| Sodium | 2 | 1977 | 331 | 0.010 |
Why?
|
| Long-Acting Thyroid Stimulator | 2 | 1974 | 3 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1984 | 130 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2004 | 123 | 0.010 |
Why?
|
| Peroxidases | 2 | 1975 | 34 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 2004 | 73 | 0.010 |
Why?
|
| Amitrole | 1 | 2003 | 3 | 0.010 |
Why?
|
| Nephrectomy | 2 | 1984 | 291 | 0.010 |
Why?
|
| Parathyroid Diseases | 1 | 1983 | 9 | 0.010 |
Why?
|
| Tyrosine | 1 | 2004 | 133 | 0.010 |
Why?
|
| Heparitin Sulfate | 1 | 2003 | 27 | 0.010 |
Why?
|
| Thyroiditis | 1 | 1983 | 10 | 0.010 |
Why?
|
| Electrophoresis | 2 | 1975 | 55 | 0.010 |
Why?
|
| Hyperparathyroidism | 1 | 1983 | 67 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2007 | 1496 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 2003 | 193 | 0.010 |
Why?
|
| Perchlorates | 2 | 2001 | 2 | 0.010 |
Why?
|
| DNA, Viral | 2 | 1996 | 262 | 0.010 |
Why?
|
| Xenopus laevis | 2 | 1995 | 138 | 0.010 |
Why?
|
| Calcineurin Inhibitors | 1 | 2004 | 53 | 0.010 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2004 | 85 | 0.010 |
Why?
|
| Fetal Resorption | 1 | 2003 | 2 | 0.010 |
Why?
|
| Freund's Adjuvant | 1 | 2003 | 26 | 0.010 |
Why?
|
| Antibodies | 3 | 1977 | 353 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2004 | 188 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 352 | 0.010 |
Why?
|
| RNA, Bacterial | 2 | 1974 | 111 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1982 | 27 | 0.010 |
Why?
|
| Hyaluronan Synthases | 1 | 1982 | 10 | 0.010 |
Why?
|
| Endocytosis | 1 | 2003 | 180 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 373 | 0.010 |
Why?
|
| Rats, Zucker | 1 | 2002 | 38 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2009 | 2878 | 0.010 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2002 | 16 | 0.010 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2002 | 28 | 0.010 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 1982 | 8 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1983 | 231 | 0.010 |
Why?
|
| Nelson Syndrome | 1 | 1982 | 3 | 0.010 |
Why?
|
| Endorphins | 1 | 1982 | 13 | 0.010 |
Why?
|
| Physical Examination | 1 | 1983 | 149 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2003 | 370 | 0.010 |
Why?
|
| Biological Clocks | 1 | 1982 | 74 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 432 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 387 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2002 | 303 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2001 | 56 | 0.010 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2001 | 18 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 2001 | 72 | 0.010 |
Why?
|
| Thiocyanates | 1 | 2001 | 11 | 0.010 |
Why?
|
| Chemical Precipitation | 2 | 1987 | 18 | 0.010 |
Why?
|
| Hypothermia | 1 | 2001 | 26 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 2001 | 72 | 0.010 |
Why?
|
| Bromocriptine | 1 | 1981 | 12 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2001 | 64 | 0.010 |
Why?
|
| Glycerolphosphate Dehydrogenase | 2 | 1980 | 8 | 0.010 |
Why?
|
| Glucuronosyltransferase | 1 | 1982 | 186 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 2502 | 0.010 |
Why?
|
| Serum Albumin, Radio-Iodinated | 2 | 1972 | 6 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2001 | 87 | 0.010 |
Why?
|
| Immunoelectrophoresis | 2 | 1972 | 19 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2006 | 947 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2001 | 105 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2000 | 72 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 1983 | 322 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 2000 | 30 | 0.010 |
Why?
|
| Feeding Behavior | 2 | 1995 | 327 | 0.010 |
Why?
|
| Ileum | 1 | 2001 | 168 | 0.010 |
Why?
|
| Blood | 2 | 1988 | 69 | 0.010 |
Why?
|
| Swine | 1 | 2002 | 588 | 0.010 |
Why?
|
| Vaccines, DNA | 1 | 2000 | 18 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 3 | 1989 | 270 | 0.010 |
Why?
|
| Solubility | 2 | 1986 | 183 | 0.010 |
Why?
|
| Liver Glycogen | 1 | 1999 | 5 | 0.010 |
Why?
|
| Extracellular Space | 1 | 2000 | 92 | 0.010 |
Why?
|
| Oculomotor Muscles | 1 | 2000 | 30 | 0.010 |
Why?
|
| Weight Gain | 1 | 2000 | 119 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2001 | 515 | 0.010 |
Why?
|
| Cricetulus | 1 | 2000 | 127 | 0.010 |
Why?
|
| Mice, Obese | 1 | 1999 | 44 | 0.010 |
Why?
|
| Edema | 1 | 2000 | 70 | 0.010 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 1999 | 12 | 0.010 |
Why?
|
| Receptors, Corticotropin | 1 | 1999 | 5 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1999 | 54 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1982 | 754 | 0.010 |
Why?
|
| United States | 2 | 1990 | 7041 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2002 | 273 | 0.010 |
Why?
|
| Spheroids, Cellular | 1 | 1999 | 31 | 0.010 |
Why?
|
| Intestine, Small | 1 | 2001 | 299 | 0.010 |
Why?
|
| Tritium | 2 | 1981 | 133 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 1999 | 120 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2000 | 147 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2001 | 711 | 0.010 |
Why?
|
| Iodoproteins | 1 | 1978 | 1 | 0.010 |
Why?
|
| Palatine Tonsil | 2 | 1975 | 30 | 0.010 |
Why?
|
| Gestational Age | 1 | 1999 | 328 | 0.010 |
Why?
|
| Biological Assay | 1 | 1978 | 79 | 0.010 |
Why?
|
| Chicago | 2 | 1991 | 1430 | 0.010 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1978 | 191 | 0.010 |
Why?
|
| Cell-Free System | 1 | 1977 | 51 | 0.010 |
Why?
|
| Poly A | 1 | 1977 | 23 | 0.010 |
Why?
|
| Infant, Premature | 1 | 1999 | 298 | 0.010 |
Why?
|
| Biological Transport, Active | 1 | 1977 | 102 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 1999 | 357 | 0.010 |
Why?
|
| Sulfites | 1 | 1977 | 31 | 0.010 |
Why?
|
| Phosphatidylinositols | 1 | 1996 | 20 | 0.010 |
Why?
|
| Vitamins | 1 | 1977 | 83 | 0.010 |
Why?
|
| Ion Exchange Resins | 3 | 1971 | 3 | 0.010 |
Why?
|
| Phylogeny | 1 | 2002 | 1191 | 0.010 |
Why?
|
| Virus Assembly | 1 | 1996 | 21 | 0.010 |
Why?
|
| Genomic Library | 1 | 1995 | 33 | 0.010 |
Why?
|
| Immunodiffusion | 2 | 1973 | 28 | 0.010 |
Why?
|
| Androgens | 1 | 1996 | 175 | 0.010 |
Why?
|
| Dwarfism, Pituitary | 2 | 1973 | 3 | 0.010 |
Why?
|
| RNA, Viral | 1 | 1977 | 318 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 1977 | 201 | 0.010 |
Why?
|
| Immune Sera | 1 | 1975 | 52 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1976 | 323 | 0.010 |
Why?
|
| Adenoids | 1 | 1975 | 9 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1975 | 171 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1995 | 418 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1995 | 203 | 0.010 |
Why?
|
| Hematocrit | 2 | 1972 | 68 | 0.010 |
Why?
|
| Anilino Naphthalenesulfonates | 1 | 1974 | 3 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1975 | 188 | 0.010 |
Why?
|
| Acne Vulgaris | 1 | 1975 | 35 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1982 | 1185 | 0.010 |
Why?
|
| Electromyography | 1 | 1995 | 195 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1974 | 109 | 0.010 |
Why?
|
| Indium | 1 | 1974 | 4 | 0.010 |
Why?
|
| Gallium | 1 | 1974 | 3 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 1977 | 337 | 0.010 |
Why?
|
| Deoxyribonucleotides | 1 | 1974 | 8 | 0.010 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 1974 | 44 | 0.010 |
Why?
|
| Polyribosomes | 1 | 1974 | 21 | 0.010 |
Why?
|
| Guanine Nucleotides | 1 | 1974 | 14 | 0.010 |
Why?
|
| Virus Replication | 1 | 1996 | 326 | 0.010 |
Why?
|
| Hypogonadism | 1 | 1974 | 40 | 0.010 |
Why?
|
| Twins | 1 | 1974 | 65 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 1977 | 1131 | 0.010 |
Why?
|
| Coliphages | 1 | 1974 | 59 | 0.010 |
Why?
|
| Adenine Nucleotides | 1 | 1974 | 63 | 0.010 |
Why?
|
| Bleomycin | 1 | 1974 | 102 | 0.010 |
Why?
|
| Estrone | 1 | 1973 | 10 | 0.010 |
Why?
|
| Infant, Premature, Diseases | 1 | 1974 | 77 | 0.010 |
Why?
|
| Diet Therapy | 1 | 1973 | 20 | 0.010 |
Why?
|
| Ribonucleases | 1 | 1974 | 93 | 0.010 |
Why?
|
| Sheep | 2 | 1972 | 251 | 0.010 |
Why?
|
| Dimethylformamide | 1 | 1973 | 2 | 0.010 |
Why?
|
| Jejunum | 1 | 1973 | 80 | 0.010 |
Why?
|
| Japan | 1 | 1994 | 305 | 0.010 |
Why?
|
| Weight Loss | 1 | 1995 | 231 | 0.010 |
Why?
|
| Nucleic Acid Denaturation | 1 | 1973 | 34 | 0.010 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 1974 | 104 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1974 | 307 | 0.010 |
Why?
|
| Lactation Disorders | 1 | 1972 | 1 | 0.010 |
Why?
|
| Cortisone | 1 | 1972 | 9 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 1974 | 211 | 0.010 |
Why?
|
| Amenorrhea | 1 | 1972 | 28 | 0.010 |
Why?
|
| Chromatography | 1 | 1972 | 28 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1972 | 91 | 0.010 |
Why?
|
| Glutens | 1 | 1973 | 84 | 0.010 |
Why?
|
| Bone Diseases, Developmental | 1 | 1972 | 11 | 0.010 |
Why?
|
| DNA, Mitochondrial | 1 | 1973 | 189 | 0.010 |
Why?
|
| RNA, Transfer | 1 | 1974 | 160 | 0.010 |
Why?
|
| Sex Factors | 2 | 1974 | 1073 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 1973 | 244 | 0.010 |
Why?
|
| Factitious Disorders | 1 | 1991 | 2 | 0.010 |
Why?
|
| Ethanol | 1 | 1974 | 252 | 0.010 |
Why?
|
| Plasma Volume | 1 | 1971 | 5 | 0.010 |
Why?
|
| Photic Stimulation | 1 | 1994 | 502 | 0.010 |
Why?
|
| Body Fluids | 1 | 1971 | 34 | 0.010 |
Why?
|
| Immunogenetics | 1 | 1971 | 7 | 0.010 |
Why?
|
| Computers | 1 | 1971 | 111 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1972 | 254 | 0.010 |
Why?
|
| Isoelectric Point | 1 | 1991 | 16 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1991 | 27 | 0.010 |
Why?
|
| Posture | 1 | 1971 | 124 | 0.010 |
Why?
|
| South Dakota | 1 | 1991 | 47 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1990 | 29 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1974 | 440 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1977 | 854 | 0.010 |
Why?
|
| Goats | 1 | 1970 | 18 | 0.010 |
Why?
|
| Secretory Rate | 1 | 1970 | 13 | 0.010 |
Why?
|
| Horses | 1 | 1970 | 35 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1970 | 172 | 0.010 |
Why?
|
| Goiter, Endemic | 1 | 1969 | 1 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1970 | 120 | 0.010 |
Why?
|
| Patient Compliance | 1 | 1991 | 230 | 0.010 |
Why?
|
| Seasons | 2 | 1981 | 239 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1970 | 245 | 0.010 |
Why?
|
| Dogs | 1 | 1970 | 704 | 0.010 |
Why?
|
| Placental Hormones | 1 | 1968 | 3 | 0.000 |
Why?
|
| 17-Ketosteroids | 1 | 1968 | 13 | 0.000 |
Why?
|
| Chromosomes, Human, 6-12 and X | 1 | 1968 | 23 | 0.000 |
Why?
|
| Hydrolysis | 1 | 1988 | 141 | 0.000 |
Why?
|
| Phenolsulfonphthalein | 1 | 1988 | 3 | 0.000 |
Why?
|
| Cognition | 1 | 1993 | 578 | 0.000 |
Why?
|
| Karyotyping | 1 | 1968 | 253 | 0.000 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1967 | 23 | 0.000 |
Why?
|
| Butyric Acid | 1 | 1987 | 11 | 0.000 |
Why?
|
| Reflex, Stretch | 1 | 1967 | 5 | 0.000 |
Why?
|
| Butyrates | 1 | 1987 | 46 | 0.000 |
Why?
|
| Antigens | 1 | 1967 | 229 | 0.000 |
Why?
|
| Receptors, Estrogen | 1 | 1988 | 394 | 0.000 |
Why?
|
| Catalase | 2 | 1975 | 49 | 0.000 |
Why?
|
| Mass Screening | 1 | 1988 | 644 | 0.000 |
Why?
|
| beta-Lipotropin | 1 | 1982 | 2 | 0.000 |
Why?
|
| beta-Endorphin | 1 | 1982 | 11 | 0.000 |
Why?
|
| False Positive Reactions | 1 | 1982 | 223 | 0.000 |
Why?
|
| Histocytochemistry | 1 | 1981 | 130 | 0.000 |
Why?
|
| Malate Dehydrogenase | 1 | 1980 | 8 | 0.000 |
Why?
|
| Blood Urea Nitrogen | 1 | 1980 | 34 | 0.000 |
Why?
|
| Umbilical Cord | 2 | 1970 | 40 | 0.000 |
Why?
|
| Globins | 1 | 1979 | 31 | 0.000 |
Why?
|
| Metabolism | 1 | 1978 | 24 | 0.000 |
Why?
|
| Trypsin | 1 | 1975 | 95 | 0.000 |
Why?
|
| Anura | 1 | 1975 | 21 | 0.000 |
Why?
|
| Antigens, Neoplasm | 1 | 1977 | 334 | 0.000 |
Why?
|
| Cytochrome Reductases | 1 | 1975 | 5 | 0.000 |
Why?
|
| Ultracentrifugation | 1 | 1975 | 42 | 0.000 |
Why?
|
| Heme | 1 | 1975 | 64 | 0.000 |
Why?
|
| Electrophoresis, Starch Gel | 1 | 1974 | 2 | 0.000 |
Why?
|
| Chloromercuribenzoates | 1 | 1974 | 5 | 0.000 |
Why?
|
| Pronase | 1 | 1974 | 5 | 0.000 |
Why?
|
| Subcellular Fractions | 1 | 1975 | 94 | 0.000 |
Why?
|
| Dithiothreitol | 1 | 1974 | 25 | 0.000 |
Why?
|
| Urea | 1 | 1974 | 59 | 0.000 |
Why?
|
| Clone Cells | 1 | 1974 | 214 | 0.000 |
Why?
|
| Peptide Fragments | 1 | 1975 | 462 | 0.000 |
Why?
|
| Cytochrome c Group | 1 | 1973 | 83 | 0.000 |
Why?
|
| Oxidoreductases | 1 | 1973 | 112 | 0.000 |
Why?
|
| Bile Acids and Salts | 1 | 1973 | 67 | 0.000 |
Why?
|
| Trichloroacetic Acid | 1 | 1972 | 1 | 0.000 |
Why?
|
| Spectrophotometry | 1 | 1972 | 108 | 0.000 |
Why?
|
| Muscles | 1 | 1972 | 193 | 0.000 |
Why?
|
| Ethchlorvynol | 1 | 1970 | 2 | 0.000 |
Why?
|
| Statistics as Topic | 1 | 1970 | 234 | 0.000 |
Why?
|
| Maternal Age | 1 | 1969 | 45 | 0.000 |
Why?
|
| Estriol | 1 | 1968 | 8 | 0.000 |
Why?
|
| Charcoal | 1 | 1968 | 13 | 0.000 |
Why?
|
| Trophoblastic Neoplasms | 1 | 1968 | 5 | 0.000 |
Why?
|
| Placental Lactogen | 1 | 1968 | 12 | 0.000 |
Why?
|
| Fetal Death | 1 | 1968 | 57 | 0.000 |
Why?
|
| Dextrans | 1 | 1968 | 79 | 0.000 |
Why?
|
| Ecuador | 1 | 1968 | 6 | 0.000 |
Why?
|
| Pregnancy in Diabetics | 1 | 1968 | 38 | 0.000 |
Why?
|
| Anthropometry | 1 | 1968 | 76 | 0.000 |
Why?
|